Late-stage trials of a COVID-19 vaccine are expected to be far enough along by November for biotech company Moderna to seek federal approval for the vaccine’s emergency use.
Late-stage trials of a COVID-19 vaccine are expected to be far enough along by November for biotech company Moderna to seek federal approval for the vaccine’s emergency use.